Carolyn Napier

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

Patrick Dorr, Mike Westby, Susan Dobbs et al. · Antimicrobial Agents and Chemotherapy · 2005 · 1.1K citations · Full text

Standard Deviations, Immunology, Pharmacotherapy +19

Profiling of cAMP and cGMP phosphodiesterases in isolated ventricular cardiomyocytes from human hearts: Comparison with rat and guinea pig

William B. Johnson, Sidath Katugampola, Sarah Able et al. · Life Sciences · 2012 · 88 citations

Cardiac Muscle, Cardiomyopathy, Heart Failure +11

Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of eletriptan binding at human 5-HT1B and 5-HT1D receptors

Carolyn Napier, Michael Stewart, Heather L. Melrose et al. · European Journal of Pharmacology · 1999 · 79 citations

Signal Transduction, Biochemistry, Functional Selectivity +8

Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc

David A. Price, Duncan Armour, Marcel de Groot et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 76 citations · Full text

Molecular Pharmacology, Ccr5 Antagonist Maraviroc, Medicine +5

Functional Selectivity of Muscarinic Receptor Antagonists for Inhibition of M3-Mediated Phosphoinositide Responses in Guinea Pig Urinary Bladder and Submandibular Salivary Gland

Carl P. Nelson, Paul Gupta, Carolyn Napier et al. · Journal of Pharmacology and Experimental Therapeutics · 2004 · 57 citations · Full text